| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Armen (Garo H.)
|
112.288k | 6.20% | +47.239k | Aug 21 2026 |
| 2 |
DRW Securities, LLC
|
41.783k | 2.31% | — | Jun 30 2026 |
| 3 |
FNY Investment Advisers LLC
|
25.000k | 1.38% | — | Jun 30 2026 |
| 4 |
Armistice Capital LLC
|
17.143k | 0.95% | — | Dec 31 2024 |
| 5 |
Virtu Americas LLC
|
0.000 | 0.00% | -18.808k | Sep 30 2025 |
|
1
Armen (Garo H.)
|
6.20%
112.288k
|
|
2
DRW Securities, LLC
|
2.31%
41.783k
|
|
3
FNY Investment Advisers LLC
|
1.38%
25.000k
|
|
4
Armistice Capital LLC
|
0.95%
17.143k
|
|
5
Virtu Americas LLC
|
0.00%
0.000
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 10.84% of Protagenic Therapeutics Inc, with Armen (Garo H.) the biggest at 6.20%, followed by DRW Securities, LLC (2.31%) and FNY Investment Advisers LLC (1.38%). |
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 26 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 23 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 19 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 14 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Oct 08 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Oct 01 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 26 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 23 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 19 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 14 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Oct 08 2026
$170.50
|
|
Lisa Park
SALES
|
Oct 01 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


